Uploaded May 2023 | Updated September 2026, 1 week ago
New research uses AlphaFold, an artificial intelligence (AI)-powered protein structure database, to accelerate the design and synthesis of a drug to treat hepatocellular carcinoma (HCC), the most common type of primary liver cancer. It is the first successful application of AlphaFold to hit identification process in drug discovery. The study was led by an international team of researchers, including Nobel Laureate in Chemistry Michael Levitt, PhD and Insilico Medicine founder and CEO Alex Zhavoronkov, PhD and published in the journal Chemical Science.
Co-authors of the study joined a fireside chat at Insilico to discuss details behind the discovery and the future of AI-powered drug discovery.
Read the full paper “AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor“ in Chemical Science, published Jan. 10, 2023: doi.org/10.1039/D2SC05709C
To learn more about Insilico Medicine: insilico.com
New research uses AlphaFold, an artificial intelligence (AI)-powered protein structure database, to accelerate the design and synthesis of a drug to treat hepatocellular carcinoma (HCC), the most common type of primary liver cancer. It is the first successful application of AlphaFold to hit identification process in drug discovery. The study was led by an international team of researchers, including Nobel Laureate in Chemistry Michael Levitt, PhD and Insilico Medicine founder and CEO Alex Zhavoronkov, PhD and published in the journal Chemical Science.
Co-authors of the study joined a fireside chat at Insilico to discuss details behind the discovery and the future of AI-powered drug discovery.
Read the full paper “AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor“ in Chemical Science, published Jan. 10, 2023: doi.org/10.1039/D2SC05709C
To learn more about Insilico Medicine: insilico.com
